Hosted on MSN22d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to knowhas approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD). The drug is approved only for use in a clinical setting under the ...
Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...
4d
GlobalData on MSNSupernus’s stock sinks after depression drug fails trialSupernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...
After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...
Around 13.2 percent of U.S. adults were using antidepressants between 2017 and 2018, according to the Centers for Disease ...
The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset missed its primary endpoint in a phase 2b trial. SPN-820 failed to improve ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results